CA2684037C - Compounds with anti-cancer activity - Google Patents

Compounds with anti-cancer activity Download PDF

Info

Publication number
CA2684037C
CA2684037C CA2684037A CA2684037A CA2684037C CA 2684037 C CA2684037 C CA 2684037C CA 2684037 A CA2684037 A CA 2684037A CA 2684037 A CA2684037 A CA 2684037A CA 2684037 C CA2684037 C CA 2684037C
Authority
CA
Canada
Prior art keywords
compound
amino
dione
trifluoromethyl
methyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CA2684037A
Other languages
English (en)
French (fr)
Other versions
CA2684037A1 (en
Inventor
Takumi Kawabe
Machiyo Ishigaki
Takuji Sato
Sayaka Yamamoto
Yoko Hasegawa
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Canbas Co Ltd
Original Assignee
Canbas Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Canbas Co Ltd filed Critical Canbas Co Ltd
Priority to CA2913840A priority Critical patent/CA2913840C/en
Publication of CA2684037A1 publication Critical patent/CA2684037A1/en
Application granted granted Critical
Publication of CA2684037C publication Critical patent/CA2684037C/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/472—Non-condensed isoquinolines, e.g. papaverine
    • A61K31/4725—Non-condensed isoquinolines, e.g. papaverine containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/44—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having three double bonds between ring members or between ring members and non-ring members
    • C07D207/444—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having three double bonds between ring members or between ring members and non-ring members having two doubly-bound oxygen atoms directly attached in positions 2 and 5
    • C07D207/448—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having three double bonds between ring members or between ring members and non-ring members having two doubly-bound oxygen atoms directly attached in positions 2 and 5 with only hydrogen atoms or radicals containing only hydrogen and carbon atoms directly attached to other ring carbon atoms, e.g. maleimide
    • C07D207/452—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having three double bonds between ring members or between ring members and non-ring members having two doubly-bound oxygen atoms directly attached in positions 2 and 5 with only hydrogen atoms or radicals containing only hydrogen and carbon atoms directly attached to other ring carbon atoms, e.g. maleimide with hydrocarbon radicals, substituted by hetero atoms, directly attached to the ring nitrogen atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/46—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with hetero atoms directly attached to the ring nitrogen atom
    • C07D207/50—Nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Pyrrole Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
CA2684037A 2007-04-11 2008-04-11 Compounds with anti-cancer activity Active CA2684037C (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CA2913840A CA2913840C (en) 2007-04-11 2008-04-11 Compounds with anti-cancer activity

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US91125807P 2007-04-11 2007-04-11
US60/911,258 2007-04-11
PCT/IB2008/003036 WO2009031040A2 (en) 2007-04-11 2008-04-11 Compounds with anti-cancer activity

Related Child Applications (1)

Application Number Title Priority Date Filing Date
CA2913840A Division CA2913840C (en) 2007-04-11 2008-04-11 Compounds with anti-cancer activity

Publications (2)

Publication Number Publication Date
CA2684037A1 CA2684037A1 (en) 2009-03-12
CA2684037C true CA2684037C (en) 2016-02-16

Family

ID=39939984

Family Applications (4)

Application Number Title Priority Date Filing Date
CA2684037A Active CA2684037C (en) 2007-04-11 2008-04-11 Compounds with anti-cancer activity
CA3188320A Pending CA3188320A1 (en) 2007-04-11 2008-04-11 Azole dione compounds with anti-cancer activity
CA3030510A Active CA3030510C (en) 2007-04-11 2008-04-11 Azole dione compounds with anti-cancer activity
CA2913840A Active CA2913840C (en) 2007-04-11 2008-04-11 Compounds with anti-cancer activity

Family Applications After (3)

Application Number Title Priority Date Filing Date
CA3188320A Pending CA3188320A1 (en) 2007-04-11 2008-04-11 Azole dione compounds with anti-cancer activity
CA3030510A Active CA3030510C (en) 2007-04-11 2008-04-11 Azole dione compounds with anti-cancer activity
CA2913840A Active CA2913840C (en) 2007-04-11 2008-04-11 Compounds with anti-cancer activity

Country Status (17)

Country Link
US (2) US8084454B2 (enExample)
EP (4) EP4074704A1 (enExample)
JP (2) JP5635396B2 (enExample)
KR (1) KR101475311B1 (enExample)
CN (2) CN101720323A (enExample)
AU (1) AU2008294410B2 (enExample)
BR (2) BRPI0810911B1 (enExample)
CA (4) CA2684037C (enExample)
DK (2) DK3567035T3 (enExample)
ES (3) ES2927954T3 (enExample)
HU (2) HUE029370T2 (enExample)
IL (4) IL289165B2 (enExample)
MX (3) MX391154B (enExample)
NZ (1) NZ580237A (enExample)
RU (1) RU2482111C2 (enExample)
WO (1) WO2009031040A2 (enExample)
ZA (1) ZA200906960B (enExample)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK3567035T3 (da) * 2007-04-11 2022-09-05 Canbas Co Ltd N-substituerede 2,5-dioxo-azolin-forbindelser til anvendelse ved behandling af cancer
EP2304436A1 (en) 2008-07-10 2011-04-06 Nodality, Inc. Methods for diagnosis, prognosis and treatment
CN102405044A (zh) * 2009-02-06 2012-04-04 南加利福尼亚大学 含有单萜的治疗组合物
US20100215644A1 (en) * 2009-02-25 2010-08-26 Nodality, Inc. A Delaware Corporation Analysis of nodes in cellular pathways
CN104744215B (zh) 2010-03-03 2019-03-15 尼昂克技术公司 包含单萜的药物组合物
US20160038600A1 (en) 2012-08-03 2016-02-11 Neonc Technologies Inc. Pharmaceutical compositions comprising poh derivatives
CN110464718A (zh) 2010-08-27 2019-11-19 尼昂克技术公司 包含poh衍生物的药物组合物
EP2651864B1 (en) 2010-12-17 2016-07-13 Neonc Technologies Inc. Methods and devices for using isoperillyl alcohol
WO2013020024A2 (en) * 2011-08-03 2013-02-07 Karyopharm Therapeutics, Inc. Maleimide compounds and methods of treatment
US9814693B2 (en) 2012-05-09 2017-11-14 Delmar Pharmaceuticals, Inc. Veterinary use of dianhydrogalactitol, diacetyldianhydrogalactitol, and dibromodulcitol to treat malignancies
KR20150021036A (ko) 2012-06-14 2015-02-27 다이이찌 산쿄 가부시키가이샤 피페리디닐피라졸로피리딘 유도체
US9682995B2 (en) 2013-01-30 2017-06-20 Bayer Pharma Aktiengesellschaft Amino-substituted isothiazoles
WO2016090355A2 (en) * 2014-12-05 2016-06-09 Massachusetts Institute Of Technology Catechol-rich polymers from n-substituted maleimides
EP4219457A1 (en) 2015-01-26 2023-08-02 Ottawa Hospital Research Institute 3-(2h)-pyridazinone derivatives, their compositions and methods for viral sensitization
CN107613768B (zh) 2015-02-12 2020-10-20 NeOnc技术股份有限公司 包含紫苏醇衍生物的药物组合物
BR112018068681A2 (pt) 2016-03-16 2019-01-15 Bayer Cropscience Ag derivados de n-(cianobenzil)-6-(ciclopropil-carbonilamino)-4-(fenil)-piridina-2-carboxamida e compostos relacionados como pesticidas e agentes de proteção de plantas
USD915100S1 (en) 2016-03-31 2021-04-06 Ocean 22, Llc Spooled item holding device
USD801721S1 (en) 2016-03-31 2017-11-07 Patricia Grayson Briden Spooled item holding device
TW201811766A (zh) 2016-08-29 2018-04-01 瑞士商諾華公司 N-(吡啶-2-基)吡啶-磺醯胺衍生物及其用於疾病治療之用途
EP3746065A4 (en) 2018-01-29 2022-02-16 Cognos Therapeutics Inc. INTRATUMORAL ADMINISTRATION OF BORTEZOMIB
EP3746451B1 (en) 2018-02-02 2023-07-12 Boehringer Ingelheim International GmbH Benzyl-, (pyridin-3-yl)methyl- or (pyridin-4-yl)methyl-substituted oxadiazolopyridine derivatives as ghrelin o-acyl transferase (goat) inhibitors
WO2019149660A1 (en) 2018-02-02 2019-08-08 Boehringer Ingelheim International Gmbh Triazolopyrimidine derivatives for use as ghrelin o-acyl transferase (goat) inhibitors
EP3749291B1 (en) 2018-02-08 2024-01-03 University of Southern California Methods of permeabilizing the blood brain barrier
EP4153599B1 (en) 2020-05-22 2024-03-13 Boehringer Ingelheim International GmbH Process for manufacturing alkyl 7-amino-5-methyl-[1,2,5]oxadiazolo[3,4-b]pyridine-carboxylate
WO2021233884A1 (en) 2020-05-22 2021-11-25 Boehringer Ingelheim International Gmbh Continuous process for manufacturing alkyl 7-amino-5-methyl-[1,2,5]oxadiazolo[3,4-b]pyridine-carboxylate
EP4415700A1 (en) * 2021-10-15 2024-08-21 The Curators of the University of Missouri Inhibitors of p1b-type atpases
CN114425054A (zh) * 2022-01-20 2022-05-03 中国人民解放军军事科学院军事医学研究院 一种蛋白酶体抑制剂Bortezomib在抗辐射损伤中的用途
CN120247782B (zh) * 2025-06-04 2025-08-19 北京颖泰嘉和生物科技股份有限公司 氟吡菌酰胺类化合物及其制备方法

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5564557A (en) * 1978-11-08 1980-05-15 Mitsui Toatsu Chem Inc Diphenyl ether compound and herbicide containing the same
IL81307A0 (en) * 1986-01-23 1987-08-31 Union Carbide Agricult Method for reducing moisture loss from plants and increasing crop yield utilizing nitrogen containing heterocyclic compounds and some novel polysubstituted pyridine derivatives
US5635966A (en) * 1994-01-11 1997-06-03 Hewlett-Packard Company Edge feed ink delivery thermal inkjet printhead structure and method of fabrication
JPH07224032A (ja) 1994-02-09 1995-08-22 Mitsui Petrochem Ind Ltd Ｎ−アリールオキシフタルイミド誘導体、その製造方 法及びそれを有効成分として含有する除草剤
JPH07244032A (ja) * 1994-03-01 1995-09-19 Ishikawajima Harima Heavy Ind Co Ltd 溶接部検査装置
US5935966A (en) * 1995-09-01 1999-08-10 Signal Pharmaceuticals, Inc. Pyrimidine carboxylates and related compounds and methods for treating inflammatory conditions
CA2230896A1 (en) * 1995-09-01 1997-03-13 Signal Pharmaceuticals, Inc. Pyrimidine carboxylates and related compounds and methods for treating inflammatory conditions
CA2245029A1 (en) * 1998-03-13 1999-09-13 University Of British Columbia Granulatimide compounds as g2 checkpoint inhibitors
US6205557B1 (en) 1998-06-09 2001-03-20 At&T Corp. Redundant call processing
US6476061B1 (en) * 1998-11-24 2002-11-05 Basf Aktiengesellschaft Fungicides containing pyrrolidones as their active agents
DE60019318T2 (de) 1999-09-22 2006-03-09 Canbas Co., Ltd., Numazu Zusammensetzungen und verfahren zur inhibierung vom zellulären g2-übergang und sensitisierung von zellen gegen dna-schädigenden wirkstoffe
CA2400224A1 (en) * 2000-02-26 2001-08-30 Basf Aktiengesellschaft Fungicidal agents containing pyrrolidones as their active agents and use thereof for treating plants
JP2002318434A (ja) * 2001-04-23 2002-10-31 Konica Corp ハロゲン化銀写真感光材料、処理方法、および画像形成方法
FR2826653B1 (fr) * 2001-06-29 2005-10-14 Servier Lab Nouveaux derives de pyrido-pyrido-pyrrolo[3,2-g]pyrrolo [3,4-e]-indole et pyrido-pyrrolo[2,3-a]pyrrolo[3,4-c] carbazole, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
JP4919598B2 (ja) * 2002-06-06 2012-04-18 株式会社 キャンバス Ｄｎａ損傷誘発性細胞周期ｇ２チェックポイントを排除し、そして／またはｄｎａ損傷処置の抗癌活性を増強する化合物
WO2005024755A2 (en) * 2002-12-31 2005-03-17 Deciphera Pharmaceuticals, Llc. Medicaments for the treatment of neurodegenerative disorders or diabetes
WO2005011573A2 (en) * 2003-08-01 2005-02-10 Auspex Pharmaceuticals, Inc. Novel therapeutic agents for the treatment of cancer, metabolic diseases and skin disorders
US7932281B2 (en) * 2004-03-10 2011-04-26 Kureha Corporation Amine-based compound and use thereof
US7973061B2 (en) * 2004-03-31 2011-07-05 Exelixis, Inc. Anaplastic lymphoma kinase modulators and methods of use
AU2006212951A1 (en) * 2005-02-08 2006-08-17 Merck & Co., Inc. Inhibitors of checkpoint kinases
WO2007022241A2 (en) * 2005-08-17 2007-02-22 Schering Corporation Novel high affinity quinoline-based kinase ligands
EP1960386A2 (en) * 2005-11-01 2008-08-27 Janssen Pharmaceutica N.V. Substituted cycloalkylpyrrolones as allosteric modulators of glucokinase
EP2005957B1 (en) * 2006-03-31 2012-05-30 Takeda Pharmaceutical Company Limited Acid secretion inhibitor
WO2008110891A2 (en) 2007-03-09 2008-09-18 Orchid Research Laboratories Limited, New heterocyclic compounds
DK3567035T3 (da) * 2007-04-11 2022-09-05 Canbas Co Ltd N-substituerede 2,5-dioxo-azolin-forbindelser til anvendelse ved behandling af cancer

Also Published As

Publication number Publication date
EP4074704A1 (en) 2022-10-19
HK1139143A1 (zh) 2010-09-10
HUE059861T2 (hu) 2023-01-28
WO2009031040A2 (en) 2009-03-12
ES2927954T3 (es) 2022-11-14
RU2482111C2 (ru) 2013-05-20
CA2684037A1 (en) 2009-03-12
DK3567035T3 (da) 2022-09-05
US20080275057A1 (en) 2008-11-06
NZ580237A (en) 2012-06-29
EP3567035B1 (en) 2022-06-01
CA3030510A1 (en) 2009-03-12
CA3030510C (en) 2023-03-14
CA2913840C (en) 2019-03-05
US8415357B2 (en) 2013-04-09
ES2732230T3 (es) 2019-12-12
CN105175394B (zh) 2018-06-08
IL242883B (en) 2022-01-01
BR122022005149B1 (pt) 2022-09-27
JP2010523644A (ja) 2010-07-15
CN101720323A (zh) 2010-06-02
EP2152692B9 (en) 2020-03-25
CN105175394A (zh) 2015-12-23
KR101475311B1 (ko) 2014-12-23
JP2014012706A (ja) 2014-01-23
EP3088397A1 (en) 2016-11-02
IL289165B2 (en) 2024-05-01
IL289165B1 (en) 2024-01-01
IL309201A (en) 2024-02-01
AU2008294410A1 (en) 2009-03-12
EP3088397B1 (en) 2019-04-10
AU2008294410B2 (en) 2012-09-06
RU2009141619A (ru) 2011-05-20
US20110092514A1 (en) 2011-04-21
US8084454B2 (en) 2011-12-27
BRPI0810911A2 (pt) 2021-03-30
EP2152692A2 (en) 2010-02-17
EP3567035A1 (en) 2019-11-13
KR20090128560A (ko) 2009-12-15
IL201380A0 (en) 2010-05-31
HUE029370T2 (hu) 2017-02-28
JP5635396B2 (ja) 2014-12-03
BRPI0810911B1 (pt) 2022-05-17
MX2009011025A (es) 2010-01-25
IL289165A (en) 2022-02-01
ES2594704T3 (es) 2016-12-22
ZA200906960B (en) 2010-12-29
DK2152692T3 (en) 2016-09-26
CA2913840A1 (en) 2009-03-12
CA3188320A1 (en) 2009-03-12
MX2020009403A (es) 2022-03-31
EP2152692B1 (en) 2016-06-15
WO2009031040A3 (en) 2009-05-14
MX374896B (es) 2025-03-04
MX391154B (es) 2025-03-21

Similar Documents

Publication Publication Date Title
CA2684037C (en) Compounds with anti-cancer activity
JP4722851B2 (ja) キノリンカリウムチャネル阻害剤
EP3653620B1 (en) New heteroaryl amide derivatives as selective inhibitors of histone deacetylases 1 and 2 (hdac1-2)
CZ299836B6 (cs) Aryl- a heteroaryl-substituované heterocyklické mocoviny, jejich použití a farmaceutické kompozice s jejich obsahem
CN107835810A (zh) 作为hdac1/2抑制剂的哌啶衍生物
CN116535400B (zh) 氮杂螺环化合物及其应用
CN109666022B (zh) 三氮唑衍生物及其制备方法和用途
HK40083024A (en) Quinoline compounds with anti-cancer activity
HK1139143B (en) Compounds with anti-cancer activity

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20130319